JP2023542297A5 - - Google Patents

Info

Publication number
JP2023542297A5
JP2023542297A5 JP2023516483A JP2023516483A JP2023542297A5 JP 2023542297 A5 JP2023542297 A5 JP 2023542297A5 JP 2023516483 A JP2023516483 A JP 2023516483A JP 2023516483 A JP2023516483 A JP 2023516483A JP 2023542297 A5 JP2023542297 A5 JP 2023542297A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
sequence shown
component
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023516483A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542297A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/075184 external-priority patent/WO2022053703A1/en
Publication of JP2023542297A publication Critical patent/JP2023542297A/ja
Publication of JP2023542297A5 publication Critical patent/JP2023542297A5/ja
Pending legal-status Critical Current

Links

JP2023516483A 2020-09-14 2021-09-14 異種プライムブーストワクチン Pending JP2023542297A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP20195872 2020-09-14
EP20195872.5 2020-09-14
EP20210671.2 2020-11-30
EP20210671 2020-11-30
EP21155814.3 2021-02-08
EP21155814 2021-02-08
EP21176373 2021-05-27
EP21176373.5 2021-05-27
PCT/EP2021/075184 WO2022053703A1 (en) 2020-09-14 2021-09-14 Heterologous prime boost vaccine

Publications (2)

Publication Number Publication Date
JP2023542297A JP2023542297A (ja) 2023-10-06
JP2023542297A5 true JP2023542297A5 (cg-RX-API-DMAC7.html) 2024-09-24

Family

ID=77897647

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023516483A Pending JP2023542297A (ja) 2020-09-14 2021-09-14 異種プライムブーストワクチン

Country Status (19)

Country Link
US (2) US20220088162A1 (cg-RX-API-DMAC7.html)
EP (1) EP4210734A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023542297A (cg-RX-API-DMAC7.html)
KR (1) KR20230069956A (cg-RX-API-DMAC7.html)
CN (1) CN116348137A (cg-RX-API-DMAC7.html)
AU (1) AU2021341521A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023001864A2 (cg-RX-API-DMAC7.html)
CA (1) CA3188236A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023000642A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023004596A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230155A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000053A (cg-RX-API-DMAC7.html)
EC (1) ECSP23027542A (cg-RX-API-DMAC7.html)
IL (1) IL300060B1 (cg-RX-API-DMAC7.html)
JO (1) JOP20230056A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023002884A (cg-RX-API-DMAC7.html)
PE (1) PE20240492A1 (cg-RX-API-DMAC7.html)
TW (1) TW202227126A (cg-RX-API-DMAC7.html)
WO (1) WO2022053703A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
EP3429618B1 (en) 2016-03-16 2024-02-21 Amal Therapeutics SA Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine
KR20190057345A (ko) 2016-09-21 2019-05-28 아말 테라퓨틱스 에스에이 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
WO2025257278A1 (en) 2024-06-12 2025-12-18 Boehringer Ingelheim International Gmbh Immunogenic sequences

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080305120A1 (en) 2004-06-17 2008-12-11 Medimmune, Inc. Immunogenic Compositions Comprising Hmgb 1 Polypeptides
DE102004034461B4 (de) 2004-07-16 2008-02-07 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
ES2291071B1 (es) 2005-06-13 2009-03-16 Proyecto De Biomedicina Cima, S.L. Agentes y metodos basados en el uso del dominio eda de la fibronectina.
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
DE09780481T1 (de) 2008-07-11 2012-01-26 Medizinische Universität Innsbruck Agonisten von nr2f6 zur immunsuppression
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
DE102008050860A1 (de) 2008-10-08 2010-04-15 Dorothee Von Laer LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
ES2655687T3 (es) 2009-09-11 2018-02-21 Proyecto De Biomedicina Cima, S.L. Composiciones terapéuticas para el tratamiento de enfermedades causadas por HPV
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
WO2011101332A1 (en) 2010-02-16 2011-08-25 Proyecto De Biomedicina Cima, S.L. Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
WO2012015979A2 (en) 2010-07-27 2012-02-02 The Regents Of The University Of California Hmgb1-derived peptides enhance immune response to antigens
US9555074B2 (en) 2010-10-08 2017-01-31 Regents Of The University Of Minnesota Annexin II compositions
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
SG11201403714TA (en) 2011-12-30 2014-07-30 Halozyme Inc Ph20 polypeptide variants, formulations and uses thereof
US9597393B2 (en) 2012-02-09 2017-03-21 Av Therapeutics, Inc. Synthetic toll-like receptor-4 (TLR-4) agonist peptides
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
KR20190057345A (ko) * 2016-09-21 2019-05-28 아말 테라퓨틱스 에스에이 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
TW202600150A (zh) * 2019-01-25 2026-01-01 德商百靈佳殷格翰國際股份有限公司 編碼ccl21之重組棒狀病毒

Similar Documents

Publication Publication Date Title
Winter et al. The structure of the gene encoding the nucleoprotein of human influenza virus A/PR/8/34
JP2023002680A5 (cg-RX-API-DMAC7.html)
FI3606942T3 (fi) Itsejärjestyviä proteiininanorakenteita, jotka esittävät paramyksovirus- ja/tai pneumovirus f -proteiineja ja niiden käyttö
JP2015509707A5 (cg-RX-API-DMAC7.html)
JP2012501959A5 (cg-RX-API-DMAC7.html)
JP2022513326A5 (cg-RX-API-DMAC7.html)
JP2016128513A5 (cg-RX-API-DMAC7.html)
JP2022502077A5 (cg-RX-API-DMAC7.html)
CA2485363A1 (en) Ferritin fusion proteins for use in vaccines and other applications
JP2012525410A5 (cg-RX-API-DMAC7.html)
JP2024508683A5 (cg-RX-API-DMAC7.html)
JP2014507146A5 (cg-RX-API-DMAC7.html)
JP2023522198A5 (cg-RX-API-DMAC7.html)
WO2014205579A4 (en) Modified matrix proteins of vesicular stomatitis virus
JP2024522385A5 (cg-RX-API-DMAC7.html)
JP2023522154A5 (cg-RX-API-DMAC7.html)
JP2023529839A5 (cg-RX-API-DMAC7.html)
US5882650A (en) Cross-reactive influenza A immunization
CN117050193B (zh) 一种β冠状病毒重组嵌合抗原、其制备方法及应用
JP2025124904A5 (cg-RX-API-DMAC7.html)
JP2005505293A5 (cg-RX-API-DMAC7.html)
JP2019532631A5 (cg-RX-API-DMAC7.html)
JP2020526202A5 (cg-RX-API-DMAC7.html)
JP2024523329A5 (cg-RX-API-DMAC7.html)
CN115850520A (zh) 新型结核病亚单位疫苗al的制备方法和应用